| Name | Title | Contact Details |
|---|
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
Biotix Holdings is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Tempest Therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.
Aphios Corp is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.